The pill is administered daily in the evening, with Apnimed planning to speak with regulatory agencies in 2026 for approval. Image credit: New Africa via Shutterstock. Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase […]
Apnimed to seek approval for sleep apnoea pill after Phase III success Read More »
Swiss Biotech Day was held in Basel, Switzerland, and brought together pharmaceutical industry leaders from across the world. Image credit: GlobalData / Abigail Beaney. As the pharma industry navigates uncertainty caused by successive moves by the US administration, including international
Power of collaboration more pertinent than ever says pharma experts Read More »
More sponsors are using AI in their clinical trials at all stages, but many areas remain unregulated that could cause issues in various areas. Image credit: Shutterstock AI image generator. AI is increasingly being adopted by sponsors for various applications
Are regulators keeping pace with AI adoption in clinical trials? Read More »
GSK and iTeos have said they are stopping all development programmes for their anti-TIGIT antibody belrestotug. Image credit: Shutterstock / FON’s Fasai. GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to
GSK and iTeos drop anti-TIGIT drug following trial failure Read More »
Most approved GLP-1RAs are administered subcutaneously. Image credit: Getty Images / Steve Christo – Corbis A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss. The observational study
GLP-1RAs show anti-cancer benefits beyond weight loss Read More »
Novo Nordisk restructures R&D organisation to drive expansion. Credit: News Øresund – Johan Wessman. Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial.
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders Read More »
Houman Ashrafian, executive vice president and head of Research and Development (R&D) at Sanofi, spoke at Swiss Biotech Day in Basel. Image credit: GlobalData / Abigail Beaney At a time when the biotech sector has been struggling with a lack
Sanofi exec tells biotechs not to scrimp on clinical trial design Read More »
This year’s theme for World Tuberculosis Day (24 March) is “Yes! We Can End TB: Commit, Invest, Deliver”. Image credit: Sabeen Zahid / Shutterstock There have been widespread reports that more effort and funding is needed to combat the TB
Rising Sirturo resistance highlights urgent need for new TB therapies Read More »
The investment landscape for biotech and biopharma has been dry in recent years. Image credit: Shutterstock / rudall30. It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst there was
how can biotech and biopharma keep trials running? Read More »
The Knight Family DIAN-TU platform trial was initiated in 2012. Image credit: Shutterstock / Orawan Pattarawimonchai. Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight Family Dominantly Inherited Alzheimer
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset Read More »
